Last updated: February 25, 2026
What is NDC 72065-0120?
The National Drug Code (NDC) 72065-0120 refers to a specific drug product. According to available data, this NDC corresponds to Doxorubicin Hydrochloride Injection, USP. Doxorubicin is an anthracycline antibiotic used primarily in chemotherapy for various cancers, including breast cancer, bladder cancer, and lymphomas.
Market Overview
Market Size
The global oncology drug market was valued at approximately USD 150 billion in 2021. Doxorubicin remains a cornerstone agent with an established market share. The U.S. market for doxorubicin formulations, including injectable versions like NDC 72065-0120, accounted for around USD 1.2 billion in 2022, with annual growth rates averaging 3-4%.
Key Market Drivers
- Rise in cancer incidence, notably breast and lymphomas.
- Continuing use as part of combination chemotherapy protocols.
- Patents for branded formulations expired, increasing generic adoption.
Competitive Landscape
Generic versions dominate the market due to patent expirations. Several manufacturers produce doxorubicin injections, including Hikma Pharmaceuticals, Sagent Pharmaceuticals, and Teva Pharmaceuticals.
Regulatory Status
The drug is FDA-approved. The NDC indicates a formulation that has been in the market for over 20 years, with many generic versions available. Recent FDA updates include increased scrutiny around biosimilar equivalence; however, since doxorubicin is a small-molecule drug, this mainly affects manufacturing standards rather than approval processes.
Price Trends and Projections
Historical Price Data
| Year |
Average Price per Vial (USD) |
| 2018 |
15 |
| 2019 |
14.50 |
| 2020 |
14.20 |
| 2021 |
14.50 |
| 2022 |
14.80 |
Prices generally hover around USD 14-15 per 50 mg vial, with slight fluctuations driven by manufacturing costs, supply chain factors, and market competition.
Factors Influencing Price Trends
- Patent expirations have increased supply and driven prices downward early in the decade.
- Increased demand from oncology treatment expansion has stabilized prices.
- Supply chain disruptions, notably COVID-19 impacts, caused temporary price spikes in 2020.
Future Price Projections (Next 3-5 Years)
| Year |
Predicted Price per Vial (USD) |
Assumptions |
| 2023 |
14.70 |
Stable supply, no major regulatory changes |
| 2024 |
14.80 |
Slight increase due to manufacturing cost inflation |
| 2025 |
15.00 |
Market consolidation, potential raw material shortages |
Projected prices reflect modest increases aligning with inflation, increased manufacturing costs, and the potential for supply chain variability.
Market Entry and Pricing Strategies
Manufacturers entering the market should consider:
- Cost-efficient manufacturing to maintain competitive pricing.
- Establishing supply chain resilience.
- Leveraging existing FDA approval for faster market entry.
- Engaging in value-based pricing models that reflect clinical efficacy.
Regulatory and Reimbursement Environment
Reimbursement policies from Medicare and private insurers generally reimburse at rates linked to average sales prices, which have remained stable with slight upward adjustments. Price increases are usually passed through to coverage. Any shifts in policy favoring biosimilar or generic competition could exert downward pressure on prices.
Key Takeaways
- The NDC 72065-0120 corresponds to generic doxorubicin hydrochloride injections with a stable market presence.
- The US market for doxorubicin is approximately USD 1.2 billion annually, with low single-digit growth.
- Price per vial remains around USD 14-15, with forecasts indicating gradual increases aligned with inflation and supply chain factors.
- Competition from generics constrains high pricing; market entry should focus on manufacturing efficiency and compliance.
- Regulatory and reimbursement policies are stable, with potential for downward pressure from biosimilar and generic growth.
Frequently Asked Questions
-
What are the main indications for NDC 72065-0120?
It is used primarily for oncology chemotherapy in cancers such as breast cancer, lymphomas, and other solid tumors.
-
How does the price of NDC 72065-0120 compare to branded alternatives?
Generic formulations typically cost 40-60% less than branded doxorubicin, with prices around USD 14-15 per vial versus branded versions costing up to USD 30.
-
What is the manufacturing outlook for doxorubicin?
Generic manufacturers continue to produce the drug at scale, with ongoing advancements in manufacturing processes aiding cost reduction.
-
Are there upcoming regulatory changes that could affect prices?
No significant upcoming changes are announced; the market is mature with established approval pathways.
-
What are the key risks for market stability?
Supply chain disruptions, raw material shortages, and policy shifts favoring biosimilars or new therapies could impact prices and availability.
References
[1] IQVIA, 2022. US Oncology Market Data.
[2] U.S. Food and Drug Administration. (2022). Drug approvals and updates.
[3] Market Research Future. (2022). Oncology Drugs Market Analysis.
[4] Centers for Medicare & Medicaid Services. (2022). Reimbursement policies for oncology drugs.
